SARS-CoV-2 mRNA疫苗接种与Graves病:12例病例报告及文献综述
该研究在新加坡单中心报告了12例在接种SARS-CoV-2 mRNA疫苗后出现Graves病相关甲状腺功能亢进(新发或复发)的患者,中位发病时间为17天,多数为女性(11/12),并回顾了文献中21例类似病例。作者提醒临床医生对易感个体接种后出现自身免疫性甲状腺疾病保持警惕,但需进一步流行病学和机制研究。
要点
- 12例患者接种SARS-CoV-2 mRNA疫苗后中位17天出现甲亢,6例新发,6例复发。
- TSH受体抗体浓度范围为2.4至32 IU/L。
- 多数患者可完成第二剂接种而无进一步加重。
核心结论
- 本病例系列提供了SARS-CoV-2疫苗接种触发Graves病患者的特征信息。
- 临床医生需对易感个体接种SARS-CoV-2疫苗后出现自身免疫性甲状腺疾病的发生或加重保持警惕。
- 需要进一步流行病学和机制研究来阐明SARS-CoV-2疫苗与甲状腺自身免疫之间可能的关联。
研究设计与样本
- 单中心病例系列,报告12例接种SARS-CoV-2 mRNA疫苗后出现甲亢的患者,并进行文献综述。
主要发现
- 12例患者甲亢发病中位时间为17天(范围5-63天),多数为女性(11/12),中位年龄35.5岁(范围22-74岁)。
- 6例为新发甲亢,另6例为既往控制良好的Graves病复发。
- TSH受体抗体浓度为2.4至32 IU/L。
- 多数患者能接种第二剂疫苗而无进一步加重。
- 文献综述发现全球其他地区报告了21例类似病例。
关键数值与推荐
- 甲亢发病中位时间17天(范围5-63天)。
- 女性11/12例,中位年龄35.5岁(范围22-74岁)。
- TSH受体抗体浓度2.4至32 IU/L。
临床怎么用
- 临床医生需对易感个体接种SARS-CoV-2疫苗后出现自身免疫性甲状腺疾病的发生或加重保持警惕。
局限性
- 需进一步流行病学和机制研究来阐明SARS-CoV-2疫苗与甲状腺自身免疫之间可能的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT AND OBJECTIVE: Thyroid autoimmunity has been reported to be associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the SARS-CoV-2 vaccination recently. We report a series of patients who presented with new onset or relapse of Graves' disease-related hyperthyroidism shortly after receiving the SARS-CoV-2 messenger RNA (mRNA) vaccine at a single tertiary institution in Singapore. METHODS AND RESULTS: We describe 12 patients who developed hyperthyroidism within a relatively short interval (median onset, 17 [range, 5-63] days) after receiving the SARS-CoV-2 mRNA vaccine. The majority were females (11/12) with median age of 35.5 (range, 22-74) years. Six patients had new-onset hyperthyroidism, whereas the other 6 had relapse of previously well-controlled Graves' disease. TSH receptor antibody concentrations ranged from 2.4 to 32 IU/L. The majority of the patients were able to go for the second dose of the vaccine without any further exacerbations. Literature review revealed 21 other similar cases reported from across the world. CONCLUSION: Our case series provides insight into the characteristics of individuals in whom Graves' disease was triggered by the SARS-CoV-2 vaccination. Clinicians need to be vigilant of precipitation or exacerbation of autoimmune thyroid disorders in predisposed individuals after exposure to the SARS-CoV-2 vaccination. Further epidemiological and mechanistic studies are required to elucidate the possible associations between the SARS-CoV-2 vaccines and the development of thyroid autoimmunity.
引用
- Chee YJ, Liew H, Hoi WH, et al. SARS-CoV-2 mRNA Vaccination and Graves' Disease: A Report of 12 Cases and Review of the Literature. J Clin Endocrinol Metab. 2022. PMID: 35235663. doi:10.1210/clinem/dgac119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。